Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (401-410 of 662) with videos related to

Pageof 67
Sort By:
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Oncotarget|May 5, 2016
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspectsMartin Culen, Marek Borsky, Veronika Nemethova, et al.
Plos One|February 3, 2012
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsKatharina Blatt, Harald Herrmann, Irina Mirkina, et al.
Cell|October 18, 2011
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesisFlorian Grebien, Oliver Hantschel, John Wojcik, et al.
Oncotarget|April 1, 2014
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemiaSabine Cerny-Reiterer, Renata A Meyer, Harald Herrmann, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Uwe Platzbecker, Martin Bornhäuser, Ulrich Germing, et al.
Oncotarget|January 22, 2015
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaSabine Cerny-Reiterer, Anja Rabenhorst, Gabriele Stefanzl, et al.
Biomarker Research|March 9, 2023
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targetedManuela Mancini, Cecilia Monaldi, Sara De Santis, et al.
International Journal of Molecular Sciences|October 28, 2023
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel ConceptsPeter Valent, Cem Akin, Michel Arock, et al.
Pageof 67

Showing results (401-410 of 662) with videos related to

Sort By:
Pageof 67
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Oncotarget|May 5, 2016
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspectsMartin Culen, Marek Borsky, Veronika Nemethova, et al.
Plos One|February 3, 2012
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsKatharina Blatt, Harald Herrmann, Irina Mirkina, et al.
Cell|October 18, 2011
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesisFlorian Grebien, Oliver Hantschel, John Wojcik, et al.
Oncotarget|April 1, 2014
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemiaSabine Cerny-Reiterer, Renata A Meyer, Harald Herrmann, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Uwe Platzbecker, Martin Bornhäuser, Ulrich Germing, et al.
Oncotarget|January 22, 2015
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaSabine Cerny-Reiterer, Anja Rabenhorst, Gabriele Stefanzl, et al.
Biomarker Research|March 9, 2023
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targetedManuela Mancini, Cecilia Monaldi, Sara De Santis, et al.
International Journal of Molecular Sciences|October 28, 2023
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel ConceptsPeter Valent, Cem Akin, Michel Arock, et al.
Pageof 67